The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change ...
Moonlake Immunotherapeutics ( ($MLTX) ) has released its Q4 earnings. Here is a breakdown of the information Moonlake Immunotherapeutics presented ...
Alzamend Neuro (ALZN) announced its plans to initiate a highly anticipated phase II clinical study of AL001 for treatment of patients with PTSD ...
"Receiving the FDA's clearance to proceed with our Phase 2 clinical trial for TPST-1495, our second clinical program, in FAP marks an important step forward in developing new treatment options for ...
Zhejiang Doer Biologics Co., Ltd. ('Doer Bio'), a clinical stage biopharmaceutical company developing innovative ...
Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced positive topline results from its ...
has completed the enrollment in the Phase 2 clinical study of DR10624 for the treatment of severe hypertriglyceridemia (SHTG) ("DR10624-201 study"). The DR10624-201 study is a randomized ...